Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Imprimer: 2151-8017
ISSN En ligne: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2015013982
pages 145-194

From Targets to Targeted Therapies in Hepatocellular Carcinoma

Melchiorre Cervello
Institute of Biomedicine and Molecular Immunology "Alberto Monroy", National Research Council (CNR) Palermo, Italy
Maria Rita Emma
Institute of Biomedicine and Molecular Immunology "Alberto Monroy", National Research Council (CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy
Giuseppa Augello
Institute of Biomedicine and Molecular Immunology "Alberto Monroy", National Research Council (CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy; Biomedical Department of internal Medicine and Specialties, University of Palermo, Via del Vespro 143, 90127
Daniele Balasus
Institute of Biomedicine and Molecular Immunology "Alberto Monroy", National Research Council (CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy
Antonina Azzolina
Institute of Biomedicine and Molecular Immunology "Alberto Monroy", National Research Council (CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy
James A. McCubrey
Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA
Antonella Cusimano
Institute of Biomedicine and Molecular Immunology "Alberto Monroy", National Research Council (CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy

RÉSUMÉ

Prognosis in advanced hepatocellular carcinoma (HCC) remains poor, despite the great improvement in the knowledge of the mechanisms behind hepatocarcinogenesis in recent years. Therapeutic options in the advanced stage of disease were quite limited until the introduction of sorafenib, a multi-kinase inhibitor. Sorafenib is considered the first systemic therapy and the only approved drug in advanced HCC. Unfortunately, sorafenib efficacy is rather limited in terms of overall survival, especially compared to results obtained with targeted therapies in other solid tumors; this limited efficacy is probably related to the heterogeneity of HCC. Consequently, a molecular characterization of HCC is urgently needed to improve treatments for and the clinical outcomes of HCC patients. This review offers a summary of the major studies regarding the signaling pathways involved in HCC pathogenesis, and an overview of the most promising drug treatments, apart from sorafenib, and the potential for their application in new therapeutic interventions in HCC.


Articles with similar content:

Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Devasis Chatterjee, Austin DeChalus, Peter J. Quesenberry, Andrew R. Mendelsohn, Joseph F. Renzulli II, Justin Q. Wang, Giovanni Camussi, Devin N. Chatterjee, Atsushi Mizokami, Evan T. Keller
Epigenetic Modifiers and Their Potential Application in Colorectal Cancer Diagnosis and Therapy
Critical Reviews™ in Oncogenesis, Vol.25, 2020, issue 2
Atul K. Tiwari, Naveen K. Vishvakarma, Dhananjay Shukla, Sapnita Shinde, Saurabh Saxena, Vineeta Dixit
Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 3
Rohit R. Bhosale, Bannimath Gurupadayya, Devegowda Vishakante Gowda, Koganti Venkata Sairam, Riyaz Ali Mahafez Ali Osmani, Rudra Vaghela, Hosahalli Veerabhadrappa Gangadharappa, Parthasarathi Keshavarao Kulkarni
Drug Development for Metastasis Prevention
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Steven M. Dubinett, Yari Fontebasso
The Effective Role of Hydroxyapatite Based Composites in Anticancer Drug Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 1
Saeed Saber-Samandari, Nader Nezafati, Samaneh Saber-Samandari